Advertisement

Topics

An Ames Test Alternative: Expression Cassettes and Methods for Detecting Transcription Errors

20:00 EDT 2 Jul 2017 | NIH

Transcription errors in RNA, though rare and transient, lead to synthesis of defective proteins. Errors in RNA transcription can cause many human diseases, including those that are age-related.

Researchers at the National Cancer Institute and Center for Cancer Research, RNA Biology Laboratory, have developed an alternative to the standard Ames test (recommended by the FDA to assess the in vivo mutagenic and carcinogenic potential of a drug for drug approval). The new assay can detect the transient errors in transcription with the potential to test the level of toxicity caused by therapeutic compounds and prevent excessively toxic drugs from entering the market.

The assay is based on suppression of a mutation in the Cre recombinase, coupled with a Cre genetic reporter to monitor the activity of the recombinase. The Cre mutation results in an inactive enzyme; errors in RNA transcription of the Cre mutation restores the activity of the enzyme. Additionally, the genetic reporter of Cre activity leads to expression of a yellow fluorescent protein (YFP) and the mouse cell line in the invention assay has both the cre mutation source and cre activatable YFP gene. Activation of the YFP gene allows for the detection of transcription errors following exposure of the cells to compounds or other treatments. Further, exposure of the cells to elevated levels of manganese results in an increase of YFP expressing cells; these results are consistent with in vitro experiments demonstrating manganese can reduce transcription accuracy.

IC: 
NCI
NIH Ref. No.: 
E-237-2016/0
Advantages: 
  • Increased accuracy in assay for detecting mutagenicity in RNA synthesis
  • Exposure of the cells to elevated levels of manganese results in an increase of YFP expressing cells; these results are consistent with in vitro experiments demonstrating manganese can reduce transcription accuracy
Applications: 
  • Assay to screen against drugs that can potentially cause RNA transcription errors
  • Assay to test the level of toxicity caused by therapeutic compounds and carcinogens
Provider Technology ID: 
3142
Updated On: 
Jul 3, 2017
Date Published: 
Monday, July 3, 2017
Provider Classifications: 
Patent Application: 
62/480,747
Publications: 
Patent Authority: 
US
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NCI
NCI
NCI
Inventor Lab URL: 
http://irp.nih.gov/pi/jeffrey-strathern
LPM FIrst Name: 
Jasmine
LPM Last Name: 
Yang
LPM Address: 
8490 Progress Drive, Riverside 5, Room 4058
LPM City: 
Frederick
Inv Is lead: 
LPM Zip: 
21701
LPM State: 
MD
LPM Phone: 
301-624-8775
LPM Suffix: 
Ph.D.
LPM Organization: 
NIH Office of Technology Transfer
LPM Fax: 
301-631-3027
DTDT Classification: 
Device
DTDT Description: 
Device
Pat Filing Date: 
2017-04-03
Technology Term: 
Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

Researchers at the NCI seek licensing partners for the assay which detects mutagenicity in RNA synthesis caused by carcinogens or therapeutic candidates.

E Number Only: 
E-237-2016
Inventor First Name: 
Jeffrey
Alison
Mary
Inventor Last Name: 
Strathern
Rattray
Ernst

Original Article: An Ames Test Alternative: Expression Cassettes and Methods for Detecting Transcription Errors

NEXT ARTICLE

More From BioPortfolio on "An Ames Test Alternative: Expression Cassettes and Methods for Detecting Transcription Errors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...